Tang, Zhenghai
Zhong, Ming-Chao
Qian, Jin
Galindo, Cristian Camilo http://orcid.org/0000-0003-2344-7756
Davidson, Dominique
Li, Jiaxin
Zhao, Yunlong http://orcid.org/0000-0002-7392-4824
Hui, Enfu
Veillette, André http://orcid.org/0000-0003-1159-4345
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research (MT-14429, MOP-82906, FDN-143338, PJT-178314 and PJT-183593)
Terry Fox Research Institute (1190-02)
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (R37 CA239072)
Article History
Received: 15 February 2023
Accepted: 5 October 2023
First Online: 9 November 2023
Competing interests
: Members of the Veillette laboratory will file a patent on the use of monoclonal antibody Z10 for the treatment of SLAMF7-positive human tumors. The authors declare no other competing interests.